Skip to content

Unprecedented hepatitis C infection rates seen in gay men in Amsterdam PrEP programme

Elske Hoornenborg at AIDS 2018. Photo by Liz Highleyman.

Dolutegravir dual therapy works well for first-time HIV treatment

Pedro Cahn and Linda-Gail Bekker at AIDS 2018. Photo by Liz Highleyman.

PrEP does not lower feminising hormone level in transgender women

Akarin Hiransuthikul and Mackenzie Cottrell at AIDS 2018. Photo by Liz Highleyman.

Rapid treatment initiation and less time with detectable HIV linked to falls in new HIV diagnoses in San Francisco and Melbourne

Alison Hughes from the San Francisco Department of Public Health at AIDS 2018. Image credit: @martinxholt

Dolutegravir: update on infant neural tube defects from Botswana

Rebecca Zash at AIDS 2018. Photo by Liz Highleyman.

Criminalisation of HIV high on agenda at AIDS 2018

Speakers at the Beyond Blame symposium. Image credit: @KatSmithson

Dolutegravir-based ART recommended for all – if reliable contraception is available

Women at the dolutegravir demonstration at AIDS 2018. ©International AIDS Society/Marten van Dijl

Brazil confirms dolutegravir is the most effective drug for first-line HIV treatment

Slide from Mariana Veloso Meireles’s presentation at AIDS 2018.

On-demand dosing as effective as daily dosing in first year of French PrEP study

Jean-Michel Molina at the Prévenir press conference. Photo by Roger Pebody.